United States - English - NLM (National Library of Medicine)

orly international inc - tolnaftate (unii: 06kb629tkv) (tolnaftate - unii:06kb629tkv) - tolnaftate 1 g in 100 ml - purpose antifungal uses effective treatment of athlete’s foot, jock itch and ringworm. not for relief of infected finger nails and toe nails or effective against bacteria or viruses. if treating athlete’s foot and ringworm: if irritation occurs or if there is no improvement within 4 weeks, discontinue use and consult a doctor. if treating jock itch: if irritation occurs or if there is no improvement within 2 weeks, discontinue use and consult a doctor. if swallowed, get medical help or contact a poison control center right away.

United States - English - NLM (National Library of Medicine)

central texas community health centers - tolnaftate (unii: 06kb629tkv) (tolnaftate - unii:06kb629tkv) - antifungal - proven clinically effective in the treatment of most athlete's foot (tinea pedis) and ringworm (tinea corporis) - helps prevent most athlete's foot with daily use - for effective relief of itching, burning and cracking

United States - English - NLM (National Library of Medicine)

nukemed, inc. dba spectronrx - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - 1 indications and usage sodium fluoride f 18 injection is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. 4 contraindications none. 8 use in specific populations 8.1 pregnancy pregnancy category c any radiopharmaceutical including sodium fluoride f18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproduction studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. 8.3 nursing mothers it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reac

United States - English - NLM (National Library of Medicine)

nukemed, inc. dba spectronrx - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - 1 indications and usage fludeoxyglucose f18 injection is indicated for positron emission tomography (pet) imaging in the following settings: 1.1 oncology for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 cardiology for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 neurology for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 4 contraindications none 8 use in specific populations 8.1 pregnancy pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not

United States - English - NLM (National Library of Medicine)

washington university school of medicine - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 37.5 mci in 1 ml - ammonia n 13 injection usp is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection.  it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taki

United States - English - NLM (National Library of Medicine)

university of north dakota - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 500 mci in 1 ml - fludeoxyglucose f 18 injection,usp is indicated in pet (positron emission tomography) for: 1. identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. fludeoxyglucose f 18 injection, usp is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. none known

United States - English - NLM (National Library of Medicine)

centre for probe development and commercialization - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 300 mci in 1 ml - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data ). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation

United States - English - NLM (National Library of Medicine)

brigham and women's hospital, inc., the - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 37.5 mci in 1 ml - ammonia n 13 injection is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection.  it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk.  because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, taking int

United States - English - NLM (National Library of Medicine)

pharmalogic south carolina, llc - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 300 mci in 1 ml - fludeoxyglucose f 18 injection, usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnoses of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventriclar dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none pregnancy category c animal reproduction studies have not been conducted with fludeoxyglucose f 18 injection. it is also not known whether fludeoxyglucose f 18 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. consider alternative diagnostic tests in a pregnant woman; administer fludeoxyglucose f 18 injection only if clearly needed. it is not known whether fludeoxyglucose f 18 injection is excreted in human milk. consider alternative diagnostic tests in women who are breast-feeding. use alternatives to breast feeding (e.g., stored breast milk or infant formula) for at least 10 half-lives of radioactive decay, if fludeoxyglucose f 18 injection is administered to a woman who is breast-feeding. the safety and effectiveness of fludeoxyglucose f 18 injection in pediatric patients with epilepsy is established on the basis of studies in adult and pediatric patients. in pediatric patients with epilepsy, the recommended dose is 2.6 mci. the optimal dose adjustment on the basis of body size or weight has not been determined. in the oncology or cardiology settings, the safety and effectiveness of fludeoxyglucose f 18 injection have not been established in pediatric patients..

United States - English - NLM (National Library of Medicine)

the university of utah dba cyclotron radiochemistry lab huntsman cancer institute - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection, usp is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f 18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproductive and developmental toxicity studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodi